Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | gastric cancer tissue, cell lines (SGC-7901, SGC-7901/DDP) |
| Expression Pattern | up-regulated |
| Function Description | In our study H19 and miR-675 were increased in gastric cancer cell lines and tissues. In addition, qRT-PCR revealed that H19 and miR-675 were overexpressed and FADD was decreased in SGC-7901/DDP, suggesting H19/miR-675 expression may be associated with cisplatin resistance |
| Pubmed ID | 28848149 |
| Year | 2017 |
| Title | Long Noncoding RNA H19/miR-675 Axis Promotes Gastric Cancer via FADD/Caspase 8/Caspase 3 Signaling Pathway |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |